MINI FUTURE SHORT - NOVO-NORDISK B | Real-time Euronext Paris 09:47:25 23/05/2024 BST | ||
| 2.965 EUR | -7.92% |
|
| Current month | -9.42% | ||
| 1 month | -16.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 2.965 | -7.92% |
| 22/05/24 | 3.22 | +3.70% |
| 21/05/24 | 3.105 | -11.54% |
| 17/05/24 | 3.51 | +4.78% |
| 16/05/24 | 3.35 | +1.82% |
Real-time Euronext Paris
Last update May 23, 2024 at 09:47 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 3GBOB | |
| ISIN | FRBNPP06LME2 |
| Date issued | 15/03/2024 |
| Strike | 1,159 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.415 € |
|---|---|
| Lowest since issue | 2.915 € |
| Spread | 0.01 € |
| Spread % | 0.34% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- 3GBOB Certificat
